reference standard comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-03-02. Numbers and descriptions here follow the published literature rather than marketing material.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
==== Absorption and distribution ==== Fomepizole distributes rapidly into total body water. The volume of distribution is between 0.6 and 1.02 L/kg. The therapeutic concentration is from 8.2 to 24.6 mg (100 to 300 micromoles) per liter. Peak concentration following single oral doses of 7 to 50 mg/kg of body weight occurred in 1 to 2 hours. The half-life varies with dose, so has not been calculated.
== Biological role == Cadmium has no known function in most organisms, and is toxic. Cadmium is considered an environmental pollutant hazardous to living organisms. A cadmium-dependent carbonic anhydrase has been found in some marine diatoms, which live in environments with low zinc concentrations. Exposure to cadmium leads to raised levels in the blood cells for a number of months. In vertebrates cadmium is preferentially absorbed in the kidneys but also in the liver and bones. Up to about 30 mg of cadmium is commonly inhaled throughout human childhood and adolescence. Cadmium is eliminated from the body in very small amounts and mainly through urine resulting in a biological half-life of 20 to 40 years. Cadmium is under research for its potential toxicity to increase the risk of cancer, cardiovascular disease, and osteoporosis.
An adnexal mass is a lump in the tissue of the adnexa of the uterus (structures which are closely related structurally and functionally to the uterus, such as the ovaries, fallopian tubes, or any of the surrounding connective tissue). Adnexal masses can be benign (noncancerous) or malignant (cancerous), and they can be categorized as simple or complex.
Sources: en.wikipedia.org
== Further reading == Sherman, R. A. (2003). "Maggot Therapy for Treating Diabetic Foot Ulcers Unresponsive to Conventional Therapy". Diabetes Care. 26 (2): 446–51. doi:10.2337/diacare.26.2.446. PMID 12547878. Van Der Plas, M. J. A.; Jukema, G. N.; Wai, S.-W.; Dogterom-Ballering, H. C. M.; Lagendijk, E. L.; Van Gulpen, C.; Van Dissel, J. T.; Bloemberg, G. V.; Nibbering, P. H. (2007). "Maggot excretions/secretions are differentially effective against biofilms of Staphylococcus aureus and Pseudomonas aeruginosa". Journal of Antimicrobial Chemotherapy. 61 (1): 117–22. doi:10.1093/jac/dkm407. PMID 17965032. Cazander, G.; Van Veen, K.E.B.; Bernards, A.T.; Jukema, G.N. (2009). "Do maggots have an influence on bacterial growth? A study on the susceptibility of strains of six different bacterial species to maggots of Lucilia sericata and their excretions/secretions". Journal of Tissue Viability. 18 (3): 80–7. doi:10.1016/j.jtv.2009.02.005. PMID 19362001. Cazander, Gwendolyn; Schreurs, Marco W. J.; Renwarin, Lennaert; Dorresteijn, Corry; Hamann, Dörte; Jukema, Gerrolt. N. (2012). "Maggot excretions affect the human complement system". Wound Repair and Regeneration. 20 (6): 879–86. doi:10.1111/j.1524-475X.2012.00850.x. PMID 23110586. S2CID 24568980. Mumcuoglu, Kosta Y.; Ingber, Arieh; Gilead, Leon; Stessman, Jochanan; Friedmann, Reuven; Schulman, Haim; Bichucher, Hellen; Ioffe-Uspensky, I; Miller, J; Galun, R; Raz, I (1999). "Maggot therapy for the treatment of intractable wounds". International Journal of Dermatology. 38 (8): 623–7. doi:10.1046/j.1365-4362.1999.00770.x.
The current consumer price inflation in Europe and the United States is less than 2%, compared to India's double digit inflation. The Pepsi and Coca-Cola example is meaningless in the context of Indian beverage market. More competition is lacking because of limited demand. Indian consumer has limited interest in soft drinks. Soft drinks represent less than 5% of Indian beverage market. Indian consumers prefer milk-based, tea and coffee and these account for 90% of Indian beverage market, with plenty of competing domestic brands and even European brands like Nestlé. The next most important market in India is bottled water, which outsells the combined soft drink sales of the Pepsi and Coca-Cola. Organised retail too will have numerous brands and strong competition. Comparing the 21st century to the 18th century is inappropriate. Conditions today are different. India wasn't a democracy then. Global awareness and news media have also changed. For example, China has over 57 million square feet of retail space owned by foreigners, employing millions of Chinese citizens. Yet, China hasn't become a vassal of imperialists, enjoying respect from all global powers. Other Asian countries like Malaysia, Taiwan, Thailand and Indonesia see foreign retailers as catalysts of new technology and price reduction; and they have benefited by welcoming FDI in retail. India too will benefit by integrating with the world, rather than isolating itself. With 51% FDI limit in multi-brand retailers, nearly half of any profits will remain in India.
An original recommendation for water intake in 1945 by the Food and Nutrition Board of the U.S. National Research Council read: "An ordinary standard for diverse persons is 1 milliliter for each calorie of food. Most of this quantity is contained in prepared foods." The latest dietary reference intake report by the U.S. National Research Council in general recommended, based on the median total water intake from US survey data (including food sources): 3.7 litres (0.81 imp gal; 0.98 US gal) for men and 2.7 litres (0.59 imp gal; 0.71 US gal) of water total for women, noting that water contained in food provided approximately 19% of total water intake in the survey. Specifically, pregnant and breastfeeding women need additional fluids to stay hydrated. The US Institute of Medicine recommends that, on average, men consume 3 litres (0.66 imp gal; 0.79 US gal) and women 2.2 litres (0.48 imp gal; 0.58 US gal); pregnant women should increase intake to 2.4 litres (0.53 imp gal; 0.63 US gal) and breastfeeding women should get 3 liters (12 cups), since an especially large amount of fluid is lost during nursing. Also noted is that normally, about 20% of water intake comes from food, while the rest comes from drinking water and beverages (caffeinated included). Water is excreted from the body in multiple forms; through urine and feces, through sweating, and by exhalation of water vapor in the breath. With physical exertion and heat exposure, water loss will increase and daily fluid needs may increase as well. Humans require water with few impurities.
== Pathophysiology == In normal metabolism, the elevated blood glucose level causes beta (β) cells in the Islets of Langerhans, located in the pancreas, to release insulin into the blood. The insulin makes insulin-sensitive tissues in the body (primarily skeletal muscle cells, adipose tissue, and liver) absorb glucose which provides energy as well as lowers blood glucose, in a negative feedback loop. The beta cells reduce insulin output as the blood glucose level falls, allowing blood glucose to settle at a homeostatic constant level of approximately 5 mmol/L (90 mg/dL). In an insulin-resistant individual, normal levels of insulin do not have the same effect in controlling blood glucose levels. When the body produces insulin under conditions of insulin resistance, the cells are unable to absorb or use glucose as effectively and it stays in the bloodstream. Certain cell types such as fat and muscle cells require insulin to absorb glucose and when these cells fail to respond adequately to circulating insulin, blood glucose levels rise. Skeletal muscle is thought to be particularly important in this regard. The liver normally helps regulate glucose levels by reducing its secretion of glucose in the presence of insulin. However, in insulin resistance, this normal reduction in the liver's glucose production may not occur, further contributing to elevated blood glucose. Also, insulin resistance often is associated with a hypercoagulable state (impaired fibrinolysis) and increased inflammatory cytokine levels.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.